Beyond Weight Loss: GLP-1 Drugs Emerge as Potential Breakthrough Therapy for Addiction to Nicotine, Alcohol, and Opioids

Over the past few years, semaglutide and tirzepatide have undoubtedly been the brightest stars in the pharmaceutical industry.

As GLP-1 (glucagon-like peptide-1) receptor agonists, they were initially developed for the treatment of type 2 diabetes, aiming to control blood glucose levels by mimicking natural hormones in the human body. However, it was soon discovered that these drugs also have anA Surprising “Side Effect”—Potent Weight-Loss Benefits.

They not only act on the pancreas and intestines to regulate blood glucose levels and satiety, but more importantly, they can cross the blood-brain barrier,It acts directly on the brain regions that regulate appetite, effectively curbing cravings for high-calorie foods.As a result, semaglutide-based medications, represented by Ozempic (for diabetes) and Wegovy (for weight loss), have rapidly gained global popularity, becoming household names as “miracle weight-loss drugs.”

But the story does not end here. As these drugs became more widely used, a more unexpected phenomenon began to emerge.

From discussion threads on online forums, to feedback from weight-loss clinics, to headline news in major media outlets, a growing number of users have reported the same peculiar experience:During weight loss treatment with these medications, their long-standing cravings for cigarettes, alcohol, and even other addictive substances inexplicably vanished.

An email received by neuroscientist Sue Grigson last April vividly illustrates this phenomenon. The sender was a man who had long struggled with opioid addiction. In desperation, he tried semaglutide. The results were beyond his own belief—he told Grigson that it was the first time in his adult life that he had completely broken free from his dependence on addictive substances and alcohol.

These rumors are not entirely baseless; the scientific community has long detected subtle clues.

As early as the early 2010s, Elisabet Jerlhag Holm, an addiction biologist at the University of Gothenburg in Sweden, keenly recognized the potential of GLP-1 drugs. She published a series of groundbreaking papers demonstratingThese drugs not only suppress rats’ craving for food but also significantly reduce their intake of alcohol, nicotine, and even potent stimulants such as amphetamines and cocaine.

However, the addiction research community at the time responded lukewarmly to these findings, and pharmaceutical giants showed little interest. It was not until 2015, when Lorenzo Leggio of the U.S. National Institutes of Health (NIH) collaborated with Jerlhag Holm to discover a direct genetic link between GLP-1 hormone and alcohol dependence in humans, that this field began to gradually gain attention.

Nowadays, with the explosive popularity of “miracle weight-loss drugs,”Relevant clinical studies have finally ushered in an explosive growth.

Earlier this year, a team led by Christian Hendershot at the University of Southern California reported the results of a landmark randomized trial:Weekly semaglutide injections effectively reduce alcohol consumption in patients with alcohol use disorder.This is the first robust clinical evidence confirming that GLP-1 drugs can alter addictive behaviors in humans.

Currently,Globally, more than a dozen relevant randomized clinical trials are currently underway in full swing.For example, Leggio and W. Kyle Simmons of Oklahoma State University are leading independent yet coordinated clinical trials in the United States to evaluate the efficacy of injectable semaglutide in individuals with moderate-to-severe alcohol use disorder; meanwhile, Joseph Schacht of the University of Colorado is exploring the potential of oral semaglutide in addiction treatment, which may offer a more patient-friendly option for those with needle aversion stemming from prior experiences with injectable substances.

Why Can a Weight-Loss Drug Help Quit Drugs and Alcohol? It May Sound Unbelievable, but Neuroscientists Point Out That It Actually Aligns with the Brain’s Underlying Logic.

Roger McIntyre, a psychopharmacologist at the University of Toronto, hit the nail on the head: “At the end of the day, being rewarded by substances,”Whether it is food, sex, or addictive drugs, the activated neurobiological system is essentially the same system.”

This system is the brain’s “reward circuit.” It connects the ventral tegmental area (VTA), which produces dopamine, with the nucleus accumbens, which receives dopamine signals to generate feelings of pleasure. Typically, gourmet food, alcohol, or addictive drugs stimulate this circuit to release dopamine, inducing a sense of euphoria in the brain and driving us to repeatedly engage in such behaviors, thereby leading to addiction.

Studies have found that GLP-1 receptors are widely distributed throughout this reward network. When drugs such as semaglutide activate these receptors, they appear to “cool down” this overactive circuit. On one hand, the drugs reduce dopamine release, making previously intoxicating alcohol or addictive substances less tempting; the “high” becomes muted, thereby blunting pleasure. On the other hand, animal studies also show that the drugs act on regions such as the amygdala, suppressing the surge in stress hormones associated with withdrawal and craving.

This means itIt not only reduces the pursuit of pleasure but also alleviates the pain and anxiety during withdrawal,thereby preventing recurrence through a dual-pronged approach.

The universality of this mechanism has excited scientists. Heath Schmidt, a neuropharmacologist at the University of Pennsylvania, pointed out that existing medications for addiction typically target only a single substance (such as methadone for opioids), whereas GLP-1 therapy could theoretically be effective against multiple sources of addiction, potentially even helping patients who simultaneously abuse multiple substances.

The potential of GLP-1 drugs in the field of addiction treatment is undoubtedly immense. If subsequent large-scale clinical trials can further confirm their efficacy, as Jerlhag Holm stated,That would be a “revolution” in the field of addiction medicine, unseen for decades.

Moreover, given the close association between the reward circuitry and cognitive functions such as learning and memory, scientists are even exploring the therapeutic potential of these drugs for cognitive disorders, including Alzheimer’s disease and depression. Although current preliminary results have been mixed—for instance, Novo Nordisk recently announced that oral semaglutide failed to meet expectations in an Alzheimer’s disease trial—the drug’s potential to improve attention and memory in patients with depression remains promising.

Of course, the road ahead is not smooth.Scientists still need to address many practical issues.: How to prevent drug-induced weight loss from harming addiction patients who already have poor nutritional status? Will patients relapse after discontinuing the medication? Furthermore, more robust clinical evidence is required to obtain approval from regulatory agencies such as the FDA.

Nevertheless,With pharmaceutical giants such as Novo Nordisk and Eli Lilly entering the field, and large-scale academic studies like those conducted by the Grigson team advancing, we have reason to remain optimistic.For countless patients mired in the quagmire of addiction and their families, this may well be the beacon of hope they have long awaited.